BioPharma Dive April 22, 2024
The acquisition of a Nexus Pharmaceuticals facility in Wisconsin could help Lilly better meet demand for injectable medicines, like those it makes for diabetes and obesity.
Dive Brief:
- Eli Lilly on Monday said it will acquire a drug plant from Nexus Pharmaceuticals to expand its manufacturing capacity for injectable medicines.
- Located in Pleasant Prairie, Wisconsin, the facility spans 84,000 square feet and recently passed inspection by the Food and Drug Administration. It doesn’t currently provide any contract manufacturing services, so will be dedicated to making Lilly drugs, the company said.
- Lilly expects production could begin by the end of next year. Reached by BioPharma Dive, a company spokesperson declined to comment on whether the company’s popular medicines for obesity...
Today's Sponsors
Today's Sponsor